Studies of human placental aromatase

Kinetic analysis of aromatization of androstenedione ( Δ 4) indicates that 3 mol of oxygen and NADPH are consumed in the formation of estrone (El). During the steady state, the 3d oxidation appears to be the rate limiting step since both 19-hydroxy and 19-oxo-androstenedione accumulate prior to El....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of steroid biochemistry 1975-03, Vol.6 (3), p.317-322
Hauptverfasser: Siiteri, Pentti K., Thompson, E.Aubrey
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 322
container_issue 3
container_start_page 317
container_title Journal of steroid biochemistry
container_volume 6
creator Siiteri, Pentti K.
Thompson, E.Aubrey
description Kinetic analysis of aromatization of androstenedione ( Δ 4) indicates that 3 mol of oxygen and NADPH are consumed in the formation of estrone (El). During the steady state, the 3d oxidation appears to be the rate limiting step since both 19-hydroxy and 19-oxo-androstenedione accumulate prior to El. Cytochrome P-450 participation in each hydroxylation step is suggested by (1) inhibition by known P-450 inhibitors other than CO, (2) inhibition by an antibody to NADPH-cytochrome c reductase, (3) spectral studies of P-450 binding of substrate and intermediates, and (4) solubilization and partial resolution of enzyme components using digitonin and DEAE cellulose. A survey of steroidal compounds has revealed that 5α-reduced androstenedione is a potent competitive inhibitor which may be of physiologic importance in control of ovarian estrogen synthesis. Finally, many steroidal drugs used in treatment of breast cancer are competitive inhibitors. The non androgenic compound 1-ene-testololactone is effective both in vitro and in vivo suggesting that antitumor activity of steroidal drugs may be due to inhibition of estrogen synthesis rather than direct androgen action.
doi_str_mv 10.1016/0022-4731(75)90149-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_83063081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0022473175901491</els_id><sourcerecordid>83063081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-5a924cafaeb2c12ff9f2a6726fe32b32793449b09bd479ef84b44dc55b77cb2c3</originalsourceid><addsrcrecordid>eNp9kMtKxDAUhrPwPvoGs-hCRBfV3Jo0G0EGbzDgQl2HJD3BSC9j0gq-va0dZunqwPkv8H8ILQm-JpiIG4wpzblk5FIWVwoTrnKyh4537yN0ktInxkSVnB6ig5JgQcUxOn_thypAyjqffQyNabNNbRy0vakzE7vG9CbBKdr3pk5wtr0L9P5w_7Z6ytcvj8-ru3XuWCH6vDCKcme8AUsdod4rT42QVHhg1DIqFeNcWaxsxaUCX3LLeeWKwkrpxghboIu5dxO7rwFSr5uQHNS1aaEbki4ZFgyXZDTy2ehil1IErzcxNCb-aIL1xENPw_U0XMtC__HQU2y57R9sA9UuNMMY5dtZhnHjd4CokwvQOqhCBNfrqgv_9_8CqK1v0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>83063081</pqid></control><display><type>article</type><title>Studies of human placental aromatase</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Siiteri, Pentti K. ; Thompson, E.Aubrey</creator><creatorcontrib>Siiteri, Pentti K. ; Thompson, E.Aubrey</creatorcontrib><description>Kinetic analysis of aromatization of androstenedione ( Δ 4) indicates that 3 mol of oxygen and NADPH are consumed in the formation of estrone (El). During the steady state, the 3d oxidation appears to be the rate limiting step since both 19-hydroxy and 19-oxo-androstenedione accumulate prior to El. Cytochrome P-450 participation in each hydroxylation step is suggested by (1) inhibition by known P-450 inhibitors other than CO, (2) inhibition by an antibody to NADPH-cytochrome c reductase, (3) spectral studies of P-450 binding of substrate and intermediates, and (4) solubilization and partial resolution of enzyme components using digitonin and DEAE cellulose. A survey of steroidal compounds has revealed that 5α-reduced androstenedione is a potent competitive inhibitor which may be of physiologic importance in control of ovarian estrogen synthesis. Finally, many steroidal drugs used in treatment of breast cancer are competitive inhibitors. The non androgenic compound 1-ene-testololactone is effective both in vitro and in vivo suggesting that antitumor activity of steroidal drugs may be due to inhibition of estrogen synthesis rather than direct androgen action.</description><identifier>ISSN: 0022-4731</identifier><identifier>DOI: 10.1016/0022-4731(75)90149-1</identifier><identifier>PMID: 810626</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Androstenedione ; Animals ; Aromatase ; Aromatase Inhibitors ; Cyanides - pharmacology ; Cytochrome P-450 Enzyme Inhibitors ; Female ; Humans ; Kinetics ; Microsomes - drug effects ; Microsomes - enzymology ; NADPH-Ferrihemoprotein Reductase - antagonists &amp; inhibitors ; Ovary - enzymology ; Oxidoreductases ; Placenta - drug effects ; Placenta - enzymology ; Placenta - ultrastructure ; Rats ; Testolactone - analogs &amp; derivatives ; Testolactone - pharmacology ; Testosterone - analogs &amp; derivatives ; Testosterone - pharmacology</subject><ispartof>Journal of steroid biochemistry, 1975-03, Vol.6 (3), p.317-322</ispartof><rights>1975</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-5a924cafaeb2c12ff9f2a6726fe32b32793449b09bd479ef84b44dc55b77cb2c3</citedby><cites>FETCH-LOGICAL-c356t-5a924cafaeb2c12ff9f2a6726fe32b32793449b09bd479ef84b44dc55b77cb2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/810626$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Siiteri, Pentti K.</creatorcontrib><creatorcontrib>Thompson, E.Aubrey</creatorcontrib><title>Studies of human placental aromatase</title><title>Journal of steroid biochemistry</title><addtitle>J Steroid Biochem</addtitle><description>Kinetic analysis of aromatization of androstenedione ( Δ 4) indicates that 3 mol of oxygen and NADPH are consumed in the formation of estrone (El). During the steady state, the 3d oxidation appears to be the rate limiting step since both 19-hydroxy and 19-oxo-androstenedione accumulate prior to El. Cytochrome P-450 participation in each hydroxylation step is suggested by (1) inhibition by known P-450 inhibitors other than CO, (2) inhibition by an antibody to NADPH-cytochrome c reductase, (3) spectral studies of P-450 binding of substrate and intermediates, and (4) solubilization and partial resolution of enzyme components using digitonin and DEAE cellulose. A survey of steroidal compounds has revealed that 5α-reduced androstenedione is a potent competitive inhibitor which may be of physiologic importance in control of ovarian estrogen synthesis. Finally, many steroidal drugs used in treatment of breast cancer are competitive inhibitors. The non androgenic compound 1-ene-testololactone is effective both in vitro and in vivo suggesting that antitumor activity of steroidal drugs may be due to inhibition of estrogen synthesis rather than direct androgen action.</description><subject>Androstenedione</subject><subject>Animals</subject><subject>Aromatase</subject><subject>Aromatase Inhibitors</subject><subject>Cyanides - pharmacology</subject><subject>Cytochrome P-450 Enzyme Inhibitors</subject><subject>Female</subject><subject>Humans</subject><subject>Kinetics</subject><subject>Microsomes - drug effects</subject><subject>Microsomes - enzymology</subject><subject>NADPH-Ferrihemoprotein Reductase - antagonists &amp; inhibitors</subject><subject>Ovary - enzymology</subject><subject>Oxidoreductases</subject><subject>Placenta - drug effects</subject><subject>Placenta - enzymology</subject><subject>Placenta - ultrastructure</subject><subject>Rats</subject><subject>Testolactone - analogs &amp; derivatives</subject><subject>Testolactone - pharmacology</subject><subject>Testosterone - analogs &amp; derivatives</subject><subject>Testosterone - pharmacology</subject><issn>0022-4731</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1975</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxDAUhrPwPvoGs-hCRBfV3Jo0G0EGbzDgQl2HJD3BSC9j0gq-va0dZunqwPkv8H8ILQm-JpiIG4wpzblk5FIWVwoTrnKyh4537yN0ktInxkSVnB6ig5JgQcUxOn_thypAyjqffQyNabNNbRy0vakzE7vG9CbBKdr3pk5wtr0L9P5w_7Z6ytcvj8-ru3XuWCH6vDCKcme8AUsdod4rT42QVHhg1DIqFeNcWaxsxaUCX3LLeeWKwkrpxghboIu5dxO7rwFSr5uQHNS1aaEbki4ZFgyXZDTy2ehil1IErzcxNCb-aIL1xENPw_U0XMtC__HQU2y57R9sA9UuNMMY5dtZhnHjd4CokwvQOqhCBNfrqgv_9_8CqK1v0g</recordid><startdate>197503</startdate><enddate>197503</enddate><creator>Siiteri, Pentti K.</creator><creator>Thompson, E.Aubrey</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197503</creationdate><title>Studies of human placental aromatase</title><author>Siiteri, Pentti K. ; Thompson, E.Aubrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-5a924cafaeb2c12ff9f2a6726fe32b32793449b09bd479ef84b44dc55b77cb2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1975</creationdate><topic>Androstenedione</topic><topic>Animals</topic><topic>Aromatase</topic><topic>Aromatase Inhibitors</topic><topic>Cyanides - pharmacology</topic><topic>Cytochrome P-450 Enzyme Inhibitors</topic><topic>Female</topic><topic>Humans</topic><topic>Kinetics</topic><topic>Microsomes - drug effects</topic><topic>Microsomes - enzymology</topic><topic>NADPH-Ferrihemoprotein Reductase - antagonists &amp; inhibitors</topic><topic>Ovary - enzymology</topic><topic>Oxidoreductases</topic><topic>Placenta - drug effects</topic><topic>Placenta - enzymology</topic><topic>Placenta - ultrastructure</topic><topic>Rats</topic><topic>Testolactone - analogs &amp; derivatives</topic><topic>Testolactone - pharmacology</topic><topic>Testosterone - analogs &amp; derivatives</topic><topic>Testosterone - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Siiteri, Pentti K.</creatorcontrib><creatorcontrib>Thompson, E.Aubrey</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of steroid biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Siiteri, Pentti K.</au><au>Thompson, E.Aubrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Studies of human placental aromatase</atitle><jtitle>Journal of steroid biochemistry</jtitle><addtitle>J Steroid Biochem</addtitle><date>1975-03</date><risdate>1975</risdate><volume>6</volume><issue>3</issue><spage>317</spage><epage>322</epage><pages>317-322</pages><issn>0022-4731</issn><abstract>Kinetic analysis of aromatization of androstenedione ( Δ 4) indicates that 3 mol of oxygen and NADPH are consumed in the formation of estrone (El). During the steady state, the 3d oxidation appears to be the rate limiting step since both 19-hydroxy and 19-oxo-androstenedione accumulate prior to El. Cytochrome P-450 participation in each hydroxylation step is suggested by (1) inhibition by known P-450 inhibitors other than CO, (2) inhibition by an antibody to NADPH-cytochrome c reductase, (3) spectral studies of P-450 binding of substrate and intermediates, and (4) solubilization and partial resolution of enzyme components using digitonin and DEAE cellulose. A survey of steroidal compounds has revealed that 5α-reduced androstenedione is a potent competitive inhibitor which may be of physiologic importance in control of ovarian estrogen synthesis. Finally, many steroidal drugs used in treatment of breast cancer are competitive inhibitors. The non androgenic compound 1-ene-testololactone is effective both in vitro and in vivo suggesting that antitumor activity of steroidal drugs may be due to inhibition of estrogen synthesis rather than direct androgen action.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>810626</pmid><doi>10.1016/0022-4731(75)90149-1</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-4731
ispartof Journal of steroid biochemistry, 1975-03, Vol.6 (3), p.317-322
issn 0022-4731
language eng
recordid cdi_proquest_miscellaneous_83063081
source MEDLINE; Alma/SFX Local Collection
subjects Androstenedione
Animals
Aromatase
Aromatase Inhibitors
Cyanides - pharmacology
Cytochrome P-450 Enzyme Inhibitors
Female
Humans
Kinetics
Microsomes - drug effects
Microsomes - enzymology
NADPH-Ferrihemoprotein Reductase - antagonists & inhibitors
Ovary - enzymology
Oxidoreductases
Placenta - drug effects
Placenta - enzymology
Placenta - ultrastructure
Rats
Testolactone - analogs & derivatives
Testolactone - pharmacology
Testosterone - analogs & derivatives
Testosterone - pharmacology
title Studies of human placental aromatase
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A23%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Studies%20of%20human%20placental%20aromatase&rft.jtitle=Journal%20of%20steroid%20biochemistry&rft.au=Siiteri,%20Pentti%20K.&rft.date=1975-03&rft.volume=6&rft.issue=3&rft.spage=317&rft.epage=322&rft.pages=317-322&rft.issn=0022-4731&rft_id=info:doi/10.1016/0022-4731(75)90149-1&rft_dat=%3Cproquest_cross%3E83063081%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=83063081&rft_id=info:pmid/810626&rft_els_id=0022473175901491&rfr_iscdi=true